Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer

NCT01674140 is registered in ClinicalTrials.gov with SWOG Cancer Research Network as lead sponsor.

NCT NCT01674140
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01674140 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase III Randomized, Placebo-Controlled Clinical Trial Evaluating the Use of Adjuvant Endocrine Therapy +/- One Year of Everolimus in Patients With High-Risk, Hormone Receptor-Positive and HER2/Neu Negative Breast Cancer
Lead sponsor
SWOG Cancer Research Network
Phase
Phase 3
Overall status
Active, not recruiting
Start date
September 12, 2013
Completion date
January 31, 2030
Enrollment
1,939 (actual)
Sites
1,459

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer